Research Analysts Offer Predictions for ESPR FY2027 Earnings

Key Points

• Investment analysts at Zacks Research have reduced their FY2027 earnings per share estimate for Esperion Therapeutics from $0.06 to $0.05, while the current consensus estimate for the year is a loss of $0.29 per share.
• Esperion Therapeutics reported a quarterly earnings per share of ($0.21), missing expectations, but achieved revenue of $65 million, surpassing analyst projections of $54.97 million.
• The stock ratings for Esperion Therapeutics vary, with two analysts giving it a hold rating and four assigning a buy rating, resulting in a consensus rating of "Moderate Buy" and a price target of $7.00.

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities researchers at Zacks Research lowered their FY2027 EPS estimates for Esperion Therapeutics in a research note issued to investors on Monday, July 28th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will earn $0.05 per share for the year, down from their prior estimate of $0.06. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share.

Other equities research analysts have also issued reports about the stock. HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, June 17th. Needham & Company LLC cut their price objective on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, The Goldman Sachs Group lowered their price objective on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $7.00.

Esperion Therapeutics Trading Down 1.4%

Shares of Esperion Therapeutics stock traded down $0.02 during midday trading on Tuesday, reaching $1.40. The company had a trading volume of 2,627,163 shares, compared to its average volume of 4,950,159. The company has a market capitalization of $277.48 million, a price-to-earnings ratio of -1.75 and a beta of 0.82. The stock has a fifty day simple moving average of $1.15 and a 200 day simple moving average of $1.34. Esperion Therapeutics has a 1-year low of $0.69 and a 1-year high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). Esperion Therapeutics had a negative net margin of 59.03% and a negative return on equity of 0.91%. The firm had revenue of $65.00 million for the quarter, compared to the consensus estimate of $54.97 million.

Institutional Investors Weigh In On Esperion Therapeutics

Large investors have recently bought and sold shares of the stock. Meridian Wealth Management LLC bought a new position in shares of Esperion Therapeutics during the first quarter valued at about $29,000. North Star Investment Management Corp. purchased a new position in Esperion Therapeutics during the second quarter valued at approximately $25,000. Sivia Capital Partners LLC purchased a new position in Esperion Therapeutics during the second quarter valued at approximately $25,000. Crestline Management LP bought a new stake in Esperion Therapeutics during the fourth quarter valued at approximately $63,000. Finally, Synergy Asset Management LLC lifted its position in Esperion Therapeutics by 3,496.3% during the first quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 30,138 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.